Lab21 launches gene test for DVT risk

Cambridge, UK-based Lab21, a provider of health and environmental diagnostics, has launched a series of genetic tests which it says allow radical new approaches to the management of thrombotic disease, including deep vein thrombosis.

The low-cost tests involve a simple cheek swab, and can be used to predict a patient's genetic risk of developing DVT, or other thrombotic disease, together with improved management of those patients who have already presented with symptoms. 10% of the population are genetically susceptible to DVT, which can be a significant risk during surgery, noted the firm, adding that as a result a large number of patients suffer post-operative clotting problems which could be circumvented if this information was available.

The thrombotic tests add to Lab21's growing portfolio of diagnostics for personalized medicine, which includes tests for heart disease, liver disease, cystic fibrosis and Sudden Infant Death Syndrome.